VANCOUVER, BC / ACCESSWIRE / October 17, 2019 / Canland Health Corp. (the “Company”) today announced that it intends to arrange the placement of up to 3,650,000 common shares priced at $0.10 per common share for total gross proceeds of up to $365,000 (the “Offering”). Proceeds from the Offering shall be used for investigating project acquisitions and general corporate purposes. The Offering is subject to regulatory approval and all securities to be issued pursuant to the Offering are subject to a four-month hold period under applicable Canadian securities laws.
The Company further announced that it has closed a previously announced seed share issuance of 4,600,000 common shares at a price per share of $0.005 for gross proceeds of $23,000 (the “Seed Share Issuance”). The common shares issued pursuant to the Seed Share Issuance are subject to a four month hold expiring on February 8, 2020.
For further information regarding this news release contact:
C.K. Cheung, CEO
Tel: 416 904 1478
On behalf of the Board of Directors
CANLAND HEALTH CORP.
THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO SELL ANY OF THE SECURITIES DESCRIBED HEREIN IN THE UNITED STATES. THESE SECURITIES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE UNITED STATED SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS UNLESS REGISTERED OR EXEMPT THEREFROM.
SOURCE: Canland Health Corp.
View source version on accesswire.com:
https://www.accesswire.com/563436/Canland-Health-Announces-Non-Brokered-Private-Placement-and-Seed-Share-Closing
– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI)…
D-bal-max D-Bal MAX Glasgow, June 15, 2025 (GLOBE NEWSWIRE) -- In the quest for enhanced…
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment…
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response…
After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients…
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were…